Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
drugs
fda
2
×
life sciences
national blog main
san francisco blog main
2
×
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
barry greene
biotech
boston
boston blog main
boston top stories
boston university
cannabidiol
dan ollendorf
dravet syndrome
epidiolex
fen-phen
fenfluramine
gw pharmaceuticals
hereditary transthyretin amyloidosis
inotersen
john berk
lennox-gastaut syndrome
mary o'donnell
national top stories
new york blog main
new york top stories
patisiran
regeneron pharmaceuticals
rna interference
san diego blog main
san diego top stories
san francisco
tafamidis
the amyloidosis foundation
the institute for clinical and economic review
vyndaqel
What
ago
2
×
fda
medicine
alnylam
approve
approved
awaits
battle
biological
cannabis
crossed
data
decades
decision
derivative
discovered
drug
epilepsy
fingers
form
friday
gw
gw’s
historic
marijuana
market
patients
pharmaceuticals
rare
rna
sets
time
trick
uses
weeks
zogenix
Language
Current search:
ago
×
fda
×
" san francisco blog main "
×
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
